IRIS
BARGAGLI, ELENA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 28.619
EU - Europa 26.548
AS - Asia 13.943
SA - Sud America 2.494
Continente sconosciuto - Info sul continente non disponibili 1.510
AF - Africa 758
OC - Oceania 57
AN - Antartide 1
Totale 73.930
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 27.954
IT - Italia 7.541
RU - Federazione Russa 5.240
SG - Singapore 4.348
CN - Cina 3.786
GB - Regno Unito 3.732
IE - Irlanda 2.996
BR - Brasile 2.047
VN - Vietnam 1.790
SE - Svezia 1.386
FR - Francia 1.371
DE - Germania 1.365
HK - Hong Kong 1.317
FI - Finlandia 825
UA - Ucraina 807
KR - Corea 565
IN - India 534
BD - Bangladesh 390
CA - Canada 371
ZA - Sudafrica 360
ES - Italia 271
NL - Olanda 266
JP - Giappone 188
IQ - Iraq 165
MX - Messico 152
PL - Polonia 151
TR - Turchia 146
AR - Argentina 138
CZ - Repubblica Ceca 112
AT - Austria 101
CI - Costa d'Avorio 94
NG - Nigeria 89
PK - Pakistan 82
EC - Ecuador 72
ID - Indonesia 70
UZ - Uzbekistan 64
BE - Belgio 62
SA - Arabia Saudita 58
IR - Iran 55
VE - Venezuela 54
MA - Marocco 50
CO - Colombia 47
PH - Filippine 47
AU - Australia 46
KE - Kenya 46
CL - Cile 40
CH - Svizzera 39
AE - Emirati Arabi Uniti 38
LT - Lituania 35
JO - Giordania 34
EG - Egitto 32
PY - Paraguay 31
PT - Portogallo 30
AZ - Azerbaigian 29
JM - Giamaica 29
MY - Malesia 28
PE - Perù 28
RO - Romania 26
IL - Israele 25
KZ - Kazakistan 23
DK - Danimarca 22
GR - Grecia 21
DZ - Algeria 20
BG - Bulgaria 19
CR - Costa Rica 19
TN - Tunisia 19
TT - Trinidad e Tobago 17
BO - Bolivia 16
NP - Nepal 16
AL - Albania 15
ET - Etiopia 14
KG - Kirghizistan 14
LB - Libano 14
LV - Lettonia 14
UY - Uruguay 14
HU - Ungheria 13
OM - Oman 13
EE - Estonia 12
HN - Honduras 12
PA - Panama 12
SN - Senegal 11
CY - Cipro 10
PS - Palestinian Territory 10
BY - Bielorussia 9
EU - Europa 9
GE - Georgia 9
LK - Sri Lanka 9
MK - Macedonia 9
NO - Norvegia 9
TH - Thailandia 9
DO - Repubblica Dominicana 8
GT - Guatemala 8
NI - Nicaragua 8
QA - Qatar 8
RS - Serbia 8
TW - Taiwan 8
LA - Repubblica Popolare Democratica del Laos 7
NZ - Nuova Zelanda 7
SC - Seychelles 7
XK - ???statistics.table.value.countryCode.XK??? 7
Totale 72.304
Salva come PNG Salva come JPEG
Città #
Dallas 4.549
Southend 3.025
Dublin 2.957
Singapore 2.580
Ashburn 2.229
Fairfield 2.071
San Jose 1.632
Moscow 1.534
Milan 1.533
Santa Clara 1.486
Chandler 1.426
Hong Kong 1.219
Council Bluffs 1.083
Beijing 944
Woodbridge 883
Siena 821
Hefei 788
Houston 788
Seattle 780
Wilmington 699
Cambridge 630
Los Angeles 607
Jacksonville 592
Rome 571
Seoul 529
Ho Chi Minh City 515
Helsinki 506
New York 506
Munich 486
Princeton 473
Hanoi 409
Florence 406
Ann Arbor 405
Lauterbourg 377
Lastra a Signa 349
The Dalles 342
Johannesburg 322
São Paulo 192
Columbus 190
Dong Ket 184
Buffalo 183
Nanjing 178
Chicago 176
Shanghai 168
Boardman 164
San Diego 159
Orem 152
London 148
Tokyo 141
Dearborn 138
Bengaluru 137
San Mateo 128
Turku 123
Frankfurt am Main 121
Málaga 120
Warsaw 120
Redondo Beach 117
Fremont 102
Figino 101
Nuremberg 99
Da Nang 96
Lappeenranta 96
Abidjan 93
Chennai 90
Turin 86
Montreal 85
Düsseldorf 82
Brooklyn 81
Toronto 80
Abuja 77
Phoenix 77
Naples 76
Nanchang 74
Haiphong 73
Stockholm 70
Atlanta 69
Denver 68
Portsmouth 68
Brno 66
Bologna 65
Washington 65
Rio de Janeiro 64
Boston 58
Manchester 58
Baghdad 57
Vienna 57
Guangzhou 56
Menlo Park 55
Amsterdam 54
San Francisco 54
Tashkent 54
Poplar 53
Catania 52
Shenyang 52
Ottawa 51
Mexico City 48
Changsha 46
Miami 44
Brussels 43
Paris 43
Totale 47.029
Salva come PNG Salva come JPEG
Nome #
La chitotriosidasi: un sensibile biomarker di sarcoidosi 1.062
A first update on mapping the human genetic architecture of COVID-19 601
ACE2 gene variants may underlie interindividual variability and susceptibility to COVID-19 in the Italian population 592
Association of toll-like receptor 7 variants with life-threatening COVID-19 disease in males: Findings from a nested case-control study 508
Genetic mechanisms of critical illness in COVID-19 452
The polymorphism L412F in TLR3 inhibits autophagy and is a marker of severe COVID-19 in males 440
Cytokine modulators in the treatment of sarcoidosis 401
Towards a functional proteomics approach to the comprehension of idiopathic pulmonary fibrosis, sarcoidosis, systemic sclerosis and pulmonary Langerhans cell histiocytosis 397
An explainable model of host genetic interactions linked to COVID-19 severity 386
Common, low-frequency, rare, and ultra-rare coding variants contribute to COVID-19 severity 382
Pathogen-sugar interactions revealed by universal saturation transfer analysis 374
Antirheumatic agents in covid-19: is IL-6 the right target? 368
Chitotriosidase: a biomarker of activity and severity in patients with sarcoidosis 367
A system biology study of BALF from patients affected by idiopathic pulmonary fibrosis (IPF) and healthy controls 358
Alveolar concentration of nitric oxide as a prognostic biomarker in idiopathic pulmonary fibrosis 356
Shorter androgen receptor polyQ alleles protect against life-threatening COVID-19 disease in European males 355
Colonizzazione e trapianto di polmone: il possibile ruolo dei colonizzanti multiresistenti sugli eventi infettivi in uno studio pilota osservazionale-retrospettivo 328
Mapping the human genetic architecture of COVID-19 325
Peripheral biomarkers' panel for severe COVID-19 patients 323
Employing a systematic approach to biobanking and analyzing clinical and genetic data for advancing COVID-19 research 319
Rare variants in Toll-like receptor 7 results in functional impairment and downregulation of cytokine-mediated signaling in COVID-19 patients 313
Long Covid: analisi di casistica in follow-up a seguito di successive ondate epidemiche 312
Bronchoalveolar lavage proteomic analysis in pulmonary fibrosis associated with systemic sclerosis: S100A6 and 14-3-3ε as potential biomarkers 311
SARS-CoV-2 susceptibility and COVID-19 disease severity are associated with genetic variants affecting gene expression in a variety of tissues 309
Evaluation of multiple-flows exhaled nitric oxide in idiopathic and non-idiopathic interstitial lung disease 307
POS0871 diagnostic accuracy og power doppler ultrasonography for the diagnosis of idiopathic inflammmatory myopathies 305
Prognostic Biomarkers of Sarcoidosis: A Comparative Study of Serum Chitotriosidase, ACE, Lysozyme, and KL-6 304
Carriers of ADAMTS13 Rare Variants Are at High Risk of Life-Threatening COVID-19 302
Accuracy of power Doppler ultrasonography in the diagnosis and monitoring of idiopathic inflammatory myopathies 298
Proteome Characterization of BALF Extracellular Vesicles in Idiopathic Pulmonary Fibrosis: Unveiling Undercover Molecular Pathways 296
Chitotriosidase and soluble IL-2 receptor: comparison of two markers of sarcoidosis severity 293
Elevated level of Galectin-1 in bronchoalveolar lavage of patients with idiopathic pulmonary fibrosis 291
Antithrombin III as predictive indicator of survival in IPF patients treated with Nintedanib: a preliminary study 290
Familial pulmonary fibrosis: Clinical and radiological characteristics and progression analysis in different high resolution-CT patterns 284
C9orf72 intermediate repeats confer genetic risk for severe covid-19 pneumonia independently of age 284
The effect of cigarette smoking on bronchoalveolar lavage protein profiles from patients with different interstitial lung diseases 283
Exhaled nitric oxide in interstitial lung diseases 278
Airway-Centered Pleuroparenchymal Fibroelastosis Associated with Non-Necrotizing Granulomas: A Rare New Entity 276
Harnessing the role of HDAC6 in Idiopathic Pulmonary Fibrosis: design, synthesis, structural analysis, and biological evaluation of potent inhibitors 275
Serial KL-6 analysis in patients with idiopathic pulmonary fibrosis treated with nintedanib 275
Gorham-Stout disease management during pregnancy 274
Idiopathic pulmonary fibrosis a rare disease with severe bone fragility 272
Adiponectin and leptin levels in idiopathic pulmonary fibrosis: A new method for BAL and serum assessment 271
Combined sarcoidosis and idiopathic pulmonary fibrosis (CSIPF): A novel disease phenotype? 270
A Comprehensive Evaluation of Mepolizumab Effectiveness in a Real-Life Setting 269
A genome-wide association study reveals evidence of association with sarcoidosis at 6p12.1 268
Increased Risk of Atherosclerosis in Patients with Sarcoidosis 267
Pirfenidone in idiopathic pulmonary fibrosis: real-life experience in the referral centre of Siena 265
Calgranulin B (S100A9/MRP14): a Key molecule in idiopathic pulmonary fibrosis? 264
Diagnosis of idiopathic pulmonary fibrosis by virtual means using “IPFdatabase”- a new software 262
Analysis of macrophage migration inhibitory factor (MIF) in patients with idiopathic pulmonary fibrosis 261
Gain- and Loss-of-Function CFTR Alleles Are Associated with COVID-19 Clinical Outcomes 260
Prognostic bioindicators in severe COVID-19 patients 258
Adaptive immune system in pulmonary sarcoidosis - comparison of peripheral and alveolar biomarkers 258
Mortality on the Waiting List for Lung Transplantation in Patients with Idiopathic Pulmonary Fibrosis: A Single-Centre Experience 256
Serial KL-6 measurements in COVID-19 patients 253
A Multidisciplinary Approach to Improve the Management of Immune-Checkpoint Inhibitor-Related Pneumonitis 252
Analysis of trace elements in bronchoalveolar lavage of patients with diffuse lung diseases 252
A real-life experience with ImmunoCAP ISAC: the advantages of a new diagnostic method 252
Omalizumab treatment in Samter's triad: case series and review of the literature 251
Carbonylated proteins in bronchoalveolar lavage of patients with sarcoidosis, pulmonary fibrosis associated with systemic sclerosis and idiopathic pulmonary fibrosis 250
Pulmonary hypertension in idiopathic pulmonary fibrosis: prevalence and clinical progress 250
Pleuroparenchymal fibroelastosis (PPFE) associated with giant cell arteritis: A coincidence or a novel phenotype? 250
Severe COVID-19 in hospitalized carriers of single CFTR pathogenic variants 248
Efficacy of pirfenidone for idiopathic pulmonary fibrosis: An Italian real life study 247
Ceruloplasmin and oxidative stress in severe eosinophilic asthma patients treated with Mepolizumab and Benralizumab 247
Serum chitotriosidase levels in patients with allergic and non-allergic asthma 246
Rituximab Therapy in Interstitial Lung Disease associated with Rheumatoid Arthritis 246
Serum amyloid A in patients with idiopathic pulmonary fibrosis 246
Higher blood eosinophil levels after omalizumab treatment may be associated with poorer asthma outcomes 246
Alveolar nitric oxide is related to periostin levels in idiopathic pulmonary fibrosis 245
BAL Proteomic Signature of Lung Adenocarcinoma in IPF Patients and Its Transposition in Serum Samples for Less Invasive Diagnostic Procedures 242
Serum levels of chitotriosidase as a marker of disease activity and clinical stage in sarcoidosis 241
AB0611 Neutrophil extracellular traps and interstitial lung disease in ANCA-associated vasculitis: a scoping review 240
Calgranulin B (S100A9) levels in bronchoalveolar lavage fluid of patients with interstitial lung diseases. 240
A functional proteomics approach to the comprehension of sarcoidosis 239
Fibrotic lung toxicity induced by cytotoxic drugs, radiation and immunotherapy in patients treated for lung cancer 239
Diagnosis of Hypersensitivity Pneumonitis in Adults: An Official ATS/JRS/ALAT Clinical Practice Guideline 238
Alveolar nitric oxide as a biomarker of COVID-19 lung sequelae: A pivotal study 237
Chitotriosidase activity in patients with interstitial lung disesaes 236
Galactin-1, 3 and 9: Potential biomarkers in idiopathic pulmonary fibrosis and other interstitial lung diseases 235
Strategies for Maximising Lung Utilisation in Donors After Brain and Cardiac Death: A Narrative Review 233
Cytokine profile and proteome analysis in bronchoalveolar lavage of patients with sarcoidosis, pulmonary fibrosis associated with systemic sclerosis and idiopathic pulmonary fibrosis 233
Asthma control in severe asthmatics under treatment with omalizumab: A cross-sectional observational study in Italy 232
NK and NKT-like cells in granulomatous and fibrotic lung diseases 232
COVID-19 pneumonia in a large cohort of patients treated with biological and targeted synthetic antirheumatic drugs 232
Krebs von den Lungen-6 as Disease Severity Marker for COVID-19 Patients: Analytical Verification and Quality Assessment of the Tosoh AIA-360 Compared to Lumipulse G600II 232
Pirfenidone in chronic lung allograft dysfunction: a single cohort study 231
Serum KL-6 concentrations as a novel biomarker of severe COVID-19 231
Bronchoalveolar lavage and serum KL-6 concentrations in chronic hypersensitivity pneumonitis: correlations with radiological and immunological features 230
Altered serum concentrations of IL-8, IL-32 and IL-10 in patients with lung impairment 6 months after COVID-19 229
Ultra-rare RTEL1 gene variants associate with acute severity of COVID-19 and evolution to pulmonary fibrosis as a specific long COVID disorder 229
BAL biomarkers’ panel for differential diagnosis of interstitial lung diseases 229
Immune-Checkpoint Expression on CD4, CD8 and NK Cells in Blood, Bronchoalveolar Lavage and Lymph Nodes of Sarcoidosis 228
Analysis of carbonylated proteins in BAL of patients with diffuse lung diseases 228
Acute exacerbation of idiopathic pulmonary fibrosis after inhalation of a water repellent 228
Idiopathic Pulmonary Fibrosis Serum proteomic analysis before and after nintedanib therapy 228
BAL and serum multiplex lipid profiling in idiopathic pulmonary fibrosis and fibrotic hypersensitivity pneumonitis 227
Cor pulmonale: the role of traditional and advanced echocardiography in the acute and chronic settings 227
Trace metals in fluids lining the respiratory system of patients with idiopathic pulmonary fibrosis and diffuse lung diseases 225
Totale 29.287
Salva come PNG Salva come JPEG
Categoria #
all - tutte 242.988
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 242.988
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/20224.148 0 593 368 305 222 157 199 211 185 526 484 898
2022/20235.729 424 592 717 691 415 1.044 359 485 447 202 213 140
2023/20245.524 218 138 517 273 294 1.280 1.644 226 62 179 179 514
2024/202512.165 715 524 1.290 671 1.397 660 611 736 943 617 1.273 2.728
2025/202630.169 2.060 3.922 3.596 3.385 5.267 1.078 3.571 886 1.093 1.963 973 2.375
2026/20272.168 1.281 887 0 0 0 0 0 0 0 0 0 0
Totale 73.930